So, on the pharma business, could you just re -share your thoughts in terms of growth and profitability over the next two-three years? How should we see this business scaling up?
Secondly, on the global biologicals business, given that now we have started getting product registrations and also building our distribution model across geographies, how should one think about the opex in this business and when do we achieve a scale where we break even on this business?
The first question is on the public hearing. Have we received any date for the public hearing or that still 1 or 2 months away?
Okay. Got it. Sir, secondly, our crushing and beneficiation come online 6 months after the EC approval. So how should we think about the ramp-up of the new pellet capacity? Will be buying iron ore from outside then? Or how should we think about our operations?
Sir, first question is on the HFO debottlenecking. We were supposed to announce the project somewhere in between the second and the third quarter. So where are we on that those timelines? And the second question is on the cGMP-4 plant. When can we expect the announcement for the cGMP-4 plant?